World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
41709
World Ranking
15857
National Ranking
41

George Fountzilas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where George Fountzilas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 791 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

George Fountzilas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where George Fountzilas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

George Fountzilas is affiliated with Aristotle University of Thessaloniki in Greece and has a research focus centered predominantly in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans several subfields including Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Surgery.

The scientist has contributed extensively to topics such as Cancer Genomics and Diagnostics, Head and Neck Cancer Studies, Lung Cancer Research Studies, Breast Cancer Treatment Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, and Ovarian Cancer Diagnosis and Treatment.

Fountzilas's publication record includes a number of recent papers, with highlights including:

  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group (2021) in Radiotherapy and Oncology
  • Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis (2021) in The Lancet Oncology
  • Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (2024) in Journal of Clinical Oncology
  • Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial (2023) in Annals of Oncology
  • Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer (2023) in Journal of Clinical Oncology

The frequent co-authors collaborating with Fountzilas include Georgia-Angeliki Koliou, Amanda Psyrri, Dimitrios Pectasides, Elena Fountzilas, and Anna Koumarianou, indicating sustained scholarly partnerships.

Major publication venues where this scientist has consistently published include Annals of Oncology, Journal of Clinical Oncology, Cancers, Anticancer Research, and ESMO Open, reflecting a focus on oncology and clinical cancer research.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis

    Pierre Blanchard;Pierre Blanchard;Anne Lee;Sophie Marguet;Julie Leclercq

  • Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

    Fergus J. Couch;Steven N. Hart;Priyanka Sharma;Amanda Ewart Toland

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

    Catherine M Phelan;Karoline B Kuchenbaecker;Karoline B Kuchenbaecker;Jonathan P Tyrer;Siddhartha P Kar

  • A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population

    Antonis C. Antoniou;Xianshu Wang;Zachary S. Fredericksen;Lesley McGuffog

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer

    Christopher A. Haiman;Gary K. Chen;Celine M. Vachon;Federico Canzian

  • Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial

    Paris Kosmidis;Nick Mylonakis;Costas Nicolaides;Charalabos Kalophonos

  • Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer A Hellenic Co-operative Oncology Group study

    D V Skarlos;E Samantas;P Kosmidis;G Fountzilas

  • What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis

    Laureen Ribassin-Majed;Sophie Marguet;Anne W.M. Lee;Wai Tong Ng

  • Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Issa J. Dahabreh;Helen Linardou;Fotios Siannis;George Fountzilas

  • A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

    G P Stathopoulos;K Syrigos;G Aravantinos;A Polyzos

  • Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

    Cornelis J A Punt;Attila Nagy;Jean-Yves Douillard;Arie Figer

  • Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

    M. Karthaus;A. Kretzschmar;H. Kröning;M. Biakhov

  • Carboplatin plus paclitaxel in unknown primary carcinoma : A phase II hellenic cooperative oncology group study

    Evangelos Briasoulis;Haralambos Kalofonos;Dimitris Bafaloukos;Epaminondas Samantas

  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

    Benjamin Lacas;Alexandra Carmel;Cécile Landais;Stuart J Wong

  • Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

    Bernard Escudier;Jan Roigas;Silke Gillessen;Ulrika Harmenberg

Frequent Co-Authors

Helen Gogas
Helen Gogas National and Kapodistrian University of Athens
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Nicholas Pavlidis
Nicholas Pavlidis University of Ioannina
Drakoulis Yannoukakos
Drakoulis Yannoukakos Aristotle University of Thessaloniki
Graham G. Giles
Graham G. Giles University of Melbourne
Heli Nevanlinna
Heli Nevanlinna University of Helsinki
Fergus J. Couch
Fergus J. Couch Mayo Clinic
Diana Eccles
Diana Eccles University of Southampton
Ute Hamann
Ute Hamann German Cancer Research Center
Irene L. Andrulis
Irene L. Andrulis University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine, the USA offers a variety of online degree options and accelerated pathways to launch or advance your healthcare career. Many registered nurses wonder, does rn to bsn require clinicals? Several programs now offer flexible solutions with minimal or no in-person clinical requirements, making it easier for working professionals to earn a BSN.

If you're aiming for advanced practice or leadership roles, exploring the shortest dnp program online can help you achieve your doctorate efficiently. There are also options for those seeking less intensive coursework, as highlighted by the easiest online dnp programs, which balance flexibility with rigorous training for higher-level nursing roles.

For prospective nurses or career changers, fast track medical programs, such as online LPN pathways, offer quicker routes into the profession. With these diverse online and accelerated options, students can tailor their education to their needs, scheduling, and career ambitions in medicine.

Best Scientists Citing George Fountzilas

Trending Scientists

Recently Published Articles